Month of Achievement: April 2026
Groundbreaking Advances in Prostate Cancer Diagnosis and Treatment
IPCSG Newsletter Feature
Introduction: A Pivotal Month for Prostate Cancer Care
April 2026 has brought remarkable progress in prostate cancer care, marked by major clinical trial results, FDA-supported initiatives, and technological breakthroughs that promise to reshape how men with prostate cancer are diagnosed and treated. From minimally invasive focal therapies to breakthrough immunotherapies, and from artificial intelligence-powered diagnostics to revolutionary combination approaches, this month exemplifies the accelerating pace of innovation in oncology. For the Informed Prostate Cancer Support Group community, understanding these developments is essential—they represent options that may soon be available at major cancer centers, including UC San Diego Moores Cancer Center.
The CAPTAIN Trial: Minimally Invasive Therapy Shows Promise
One of April 2026's most significant announcements came from the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, where results from the CAPTAIN Trial demonstrated that a minimally invasive focal therapy may offer advantages over traditional surgery for men with intermediate-risk localized prostate cancer.
What Is TULSA and Why It Matters
The trial evaluated MRI-guided transurethral ultrasound ablation (TULSA), a technique performed by interventional radiologists that uses real-time magnetic resonance imaging to guide targeted ultrasound energy through the urethra, precisely heating and destroying cancerous tissue. Unlike radical prostatectomy (surgical removal of the entire prostate), TULSA preserves the rest of the gland while ablating only the cancer-bearing region.
CAPTAIN Trial Overview: A randomized clinical study of 212 men across 23 medical centers (2022–2025) compared TULSA with robotic prostate surgery in men with intermediate-risk, localized prostate cancer.
Key Results
The findings are clinically significant. TULSA patients experienced:
- Less blood loss and same-day discharge compared to multi-day hospital stay for surgery
- Lower pain levels in the immediate postoperative period
- Faster recovery at one month, with quicker return to normal activities
- Potential for better preservation of urinary and sexual function long-term
Dr. David Woodrum, primary investigator at Mayo Clinic, noted: "These early results suggest that TULSA may allow patients to recover more quickly and maintain a better quality of life following treatment, while still effectively treating the cancer."
While longer-term cancer control and functional outcome data are still being collected, the CAPTAIN Trial represents a major step toward offering men with localized intermediate-risk disease an alternative that balances oncologic efficacy with quality of life preservation.
VIR-5500: A New Generation of T-Cell Engager Immunotherapy Advances
Meanwhile, at the 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium in San Francisco, a breakthrough immunotherapy called VIR-5500 demonstrated remarkable early-stage efficacy in heavily pre-treated men with advanced prostate cancer—a population with very limited treatment options.
Understanding T-Cell Engagers and VIR-5500
VIR-5500 is a PSMA-targeting, dual-masked T-cell engager—part of a new class of immunotherapies that work by physically linking T-cells (immune cells) with prostate cancer cells. Unlike older checkpoint inhibitors that have failed in prostate cancer, T-cell engagers use a "bispecific antibody" approach: one end binds to PSMA protein on cancer cell surfaces, while the other end binds to CD3 on T-cells. This enforced proximity activates T-cells to kill cancer cells directly.
Clinical Efficacy That Surprises Experts
In the phase 1 dose-escalation trial, initial findings presented in April proved exceptional:
VIR-5500 Phase 1 Results: Among patients receiving the highest doses of VIR-5500, 82% experienced reductions in PSA levels. Remarkably, nearly 50% of these heavily pre-treated patients showed actual tumor shrinkage at both primary tumor sites and in metastatic lesions that had spread from the prostate.
Dr. Johann de Bono, director of the drug development unit at the Institute of Cancer Research and principal investigator, observed: "It is remarkable to see these early signs of profound anti-tumor activity in heavily pre-treated mCRPC patients, and the favorable tolerability with minimal CRS [cytokine release syndrome] to date means VIR-5500 could play a role in treating earlier disease."
Perhaps most importantly, the toxicity profile was manageable. Most patients tolerated the drug well with minimal cytokine release syndrome—a toxicity that plagued earlier-generation T-cell engagers. The trial is expanding into additional cohorts, including combination studies with enzalutamide in earlier-stage metastatic disease. Sponsors have announced plans to initiate pivotal phase 3 trials in 2027, potentially opening a path to FDA approval within the next 2–3 years.
Radioligand Therapy Plus SBRT: Combination Strategy Doubles Progression-Free Survival
April also saw continued momentum for a combination approach that integrates radioligand therapy (radiopharmaceutical treatment targeting PSMA) with stereotactic body radiation therapy (SBRT). Published in the Journal of Clinical Oncology and presented at the American Society for Radiation Oncology meeting earlier this year, UCLA Health researchers demonstrated that sequencing these two therapies produced dramatic benefits.
The Clinical Problem Being Addressed
Some men develop prostate cancer recurrence after initial treatment, but in a limited way—only a few lesions are visible on imaging (called "oligorecurrent disease"). SBRT has become popular for targeting these visible lesions. However, microscopic disease too small to detect on scans often remains, leading to eventual relapse.
The Solution: Add Radioligand First
Researchers tested whether adding PSMA-targeted radioligand therapy before SBRT would eliminate both visible and microscopic disease. The results were compelling:
UCLA Combination Trial Results: Men who received radioligand therapy followed by SBRT went a median of 17.6 months without disease progression, compared with only 7.4 months for SBRT alone—a more than two-fold improvement. Additionally, men in the combination arm delayed the need for hormone therapy by a median of 24.3 months versus 14.1 months in the SBRT-only group.
Importantly, researchers also identified biological markers that may help predict which patients will benefit most from this combination approach, opening the door to more personalized treatment selection.
Focal Therapy's Evolution: IPCU 2026 Conference Highlights Emerging Options
At the 2026 International Prostate Cancer Update (IPCU) conference in February—with additional recent data presented in April—experts examined the growing role of focal therapies as a middle ground between active surveillance and whole-gland treatment. Dr. Behfar Ehdaie from Memorial Sloan Kettering emphasized that focal therapy addresses a critical clinical gap for men who don't want to watch cancer grow but also wish to avoid the side effects of complete prostate removal or radiation.
Irreversible Electroporation (IRE): The NanoKnife Approach
Irreversible electroporation using the NanoKnife system has emerged as a particularly promising focal therapy. Rather than heat (like thermal ablation) or radiation, IRE uses short pulses of high-voltage electrical current to create irreversible cell membrane damage in cancer cells, essentially destroying them through electroporation. Key advantages include:
- Minimal thermal injury to surrounding structures (nerves, blood vessels, urethra preserved)
- Possible immune activation at the ablation site, triggering anti-tumor immune response
- Shorter recovery compared to surgery
- Lower morbidity, particularly for sexual and urinary function
Recent systematic reviews (through 2024) analyzing 899 patients treated with IRE for localized prostate cancer found in-field recurrence rates of 0–39% and out-of-field recurrence rates of 4–28%, with most recurrences remaining localized and retreatable. As Dr. Ehdaie noted, focal therapy, like active surveillance and robotic prostatectomy before it, is gaining acceptance even as randomized evidence continues to accumulate.
Artificial Intelligence: Transforming Diagnosis and Personalized Care
One of the most transformative developments of April 2026 involves artificial intelligence reshaping prostate cancer diagnosis and treatment planning. Recent publications in npj Digital Medicine, the Journal of Medical Internet Research, and other peer-reviewed journals document AI's expanding role across the entire diagnostic spectrum.
AI-Powered Imaging Interpretation
Machine learning and deep learning algorithms are now enhancing detection and characterization of prostate cancer on multiparametric MRI (mpMRI) and PSMA-PET/CT imaging. AI models achieve diagnostic accuracy often matching—and sometimes exceeding—expert radiologists, with median diagnostic accuracy (AUC-ROC) of 0.88 across studies analyzing over 23,000 patients published between 2015 and April 2025. Beyond accuracy, AI delivers speed: reporting time decreases by up to 56% compared to manual interpretation.
Digital Pathology and Gleason Grading
In the pathology laboratory, deep learning algorithms now provide automated, consistent Gleason grading of biopsy specimens, reducing inter-observer variability that has historically plagued prostate cancer prognosis assessment. One April 2026 study demonstrated that AI models could accurately classify atypical glands and borderline morphologies on H&E-stained slides with AUC values of 0.951–0.993, potentially reducing the need for immunohistochemistry (IHC) staining—a process that adds cost and time to diagnosis.
Multi-Omics and Precision Medicine
Most promisingly, multimodal AI models now integrate imaging data, biomarker results, genomic information, and clinical variables to create comprehensive prediction tools. These systems help:
- Identify men with low-risk disease who can safely pursue active surveillance
- Predict which patients will benefit from specific systemic therapies (hormone therapy, chemotherapy, immunotherapy)
- Forecast treatment toxicity before therapy begins, enabling preventive interventions
- Optimize radiation therapy planning through automated organ contouring
The clinical integration of these AI tools remains a work in progress, with ongoing multicenter randomized controlled trials (like NCT05513638, which began enrolling in 2023) comparing AI-assisted versus human-only interpretation of prostate cancer diagnostic imaging.
PARP Inhibitors: Rapid Expansion of a Precision Medicine Approach
An April 2025 analysis published in Cancer reviewed 630 registered clinical trials involving prostate cancer and PARP inhibitors, finding 109 trials meeting inclusion criteria. PARP inhibitors target homologous recombination repair (HRR) deficiencies in cancer cells, offering a precision medicine strategy for men whose tumors carry specific DNA repair mutations.
Key findings from this landscape analysis:
PARP Inhibitor Trial Landscape: Significant increase in trials from 2012 to 2025; 39.4% were multinational collaborative studies with the United States as the principal contributing country. Most trials target PARP1 and PARP2 at various phases of development, from phase 1 through phase 3. PARP inhibitors have demonstrated breakthrough advancements in treating metastatic castration-resistant prostate cancer (mCRPC), though challenges such as resistance mechanisms and the need for patient selection persist.
This rapid expansion reflects growing recognition that genomic testing—identifying which men have HRR mutations—enables matching them to PARP inhibitors for potentially superior outcomes.
Exercise During ADT: New Evidence for Benefit
As men spend longer periods on hormone therapy, understanding how to mitigate metabolic and functional decline becomes critical. A 2025 randomized controlled trial examining exercise efficacy and safety in men undergoing ADT found supportive evidence for current guidelines recommending 3 times weekly aerobic exercise plus 2 times weekly resistance training. Exercise was not only safe but delivered measurable benefits in lean muscle preservation, metabolic function, fatigue reduction, and mood—all critical factors for quality of life during long-term ADT.
The Bigger Picture: What These Advances Mean for IPCSG Members
April 2026's breakthroughs reflect a fundamental shift in prostate cancer care toward personalization, preservation of function, and earlier intervention with increasingly effective therapies. Several themes emerge:
1. More Treatment Options Across Disease Stages
Men with localized disease now have a spectrum of choices: active surveillance, focal therapies (laser, cryoablation, IRE, TULSA), robotic surgery, SBRT, or conventional radiation. Shared decision-making with your oncology team is essential to find the approach that aligns with your values and life circumstances.
2. Precision Medicine Is Moving Beyond Concept to Clinical Reality
Genomic testing, biomarker-driven therapy selection, and AI-powered prediction tools are no longer research concepts—they're being integrated into standard care at major academic centers. Ask your physician whether genomic testing or AI-assisted diagnostics are available to guide your care.
3. Combination Strategies Are Delivering Better Results
The UCLA radioligand + SBRT trial exemplifies a shift toward thoughtfully sequenced combination therapies that target disease at multiple levels. Similarly, T-cell engagers may be combined with other immunotherapy approaches or hormone therapies.
4. Immunotherapy Is Finally Gaining Traction in Prostate Cancer
For decades, immunotherapy largely failed in prostate cancer. VIR-5500 and other T-cell engagers represent a fundamental breakthrough, offering hope to men with treatment-resistant metastatic disease and potentially advancing into earlier disease settings.
5. Quality of Life Outcomes Are Central to Modern Care
From TULSA's focus on faster recovery to focal therapy's preservation of function to exercise guidelines during ADT, modern prostate cancer care increasingly emphasizes not just extending survival but maintaining the life worth living. This represents a profound shift in how success is measured.
Looking Ahead
The achievements announced in April 2026 are not endpoints but waypoints on a trajectory toward even more effective treatments with fewer side effects. Pivotal phase 3 trials for T-cell engagers are planned for 2027. Longer-term data on focal therapies continues to accumulate. AI-driven diagnostic and treatment planning tools are moving from research settings into standard clinical practice. For men with prostate cancer and their families, staying informed about these advances—and asking your care team how they apply to your situation—has never been more important. The IPCSG community remains committed to translating this evolving evidence into patient-friendly information that empowers informed decision-making at every stage of the prostate cancer journey.
Sources and Citations
1. CAPTAIN Trial: MRI-Guided TULSA Results
Applied Radiation Oncology. "SIR 2026 Study Finds Minimally Invasive Prostate Cancer Therapy Linked to Faster Recovery." Study presented at SIR 2026 Annual Scientific Meeting, April 2026. Primary Investigator: David A. Woodrum, MD, Mayo Clinic.
https://www.appliedradiationoncology.com/articles/sir-2026-study-finds-minimally-invasive-prostate-cancer-therapy-linked-to-faster-recovery
2. VIR-5500 T-Cell Engager Phase 1 Results
Urology Times. "VIR-5500 Enters Expansion Cohorts in Phase 1 Trial for Metastatic Prostate Cancer." Presented at 2026 ASCO GU Cancers Symposium, San Francisco, CA. Accessed April 13, 2026. Principal Investigator: Johann de Bono, MBChB, PhD, Institute of Cancer Research.
https://www.urologytimes.com/view/vir-5500-enters-expansion-cohorts-in-phase-1-trial-for-metastatic-prostate-cancer
3. T-Cell Engager Mechanisms and Clinical Development
Kwon W-A, Joung JY. "T-Cell Engager Therapy in Prostate Cancer: Molecular Insights into a New Frontier in Immunotherapy." Cancers, vol. 17, no. 11, 2025, article 1820. DOI: 10.3390/cancers17111820.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12153726/
4. UCLA Radioligand + SBRT Combination Trial
UCLA Health. "New Therapy Delays Progression of Recurrent Prostate Cancer." Clinical trial results published in Journal of Clinical Oncology and presented at American Society for Radiation Oncology Annual Meeting, 2025. Accessed November 12, 2025.
https://www.uclahealth.org/news/release/new-therapy-delays-progression-recurrent-prostate-cancer
5. Focal Therapy Update: IPCU 2026
Ehdaie B. "Focal Therapy Update: Selection, Outcomes, Trials." Grand Rounds in Urology. February 2026. Presenter: Associate Attending Surgeon, Memorial Sloan Kettering Cancer Center, New York, NY.
https://grandroundsinurology.com/focal-therapy-update-selection-outcomes-trials/
6. Irreversible Electroporation (IRE) for Prostate Cancer
Zhou Y, et al. "Irreversible Electroporation in Focal Therapy for Prostate Cancer: Current Status and Future Directions." ScienceDirect, 2025. Published November 7, 2025. Comprehensive review of IRE mechanisms, clinical outcomes, and patient selection.
https://www.sciencedirect.com/science/article/pii/S2287888225000935
7. Systematic Review: IRE as Focal Therapy
Crouzet S, et al. "Irreversible Electroporation as a Focal Therapy for Localized Prostate Cancer: A Systematic Review." Journal of Endourology, 2024. Analysis of 14 studies involving 899 patients; evaluated in-field and out-of-field recurrence rates.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10836445/
8. AI in Prostate Cancer Diagnostic Imaging
Canellas R, et al. "Application and Prospect of Artificial Intelligence in Diagnostic Imaging of Prostate Cancer." npj Digital Medicine, vol. 9, article 168, 2026. DOI: 10.1038/s41746-026-02354-6. Published August 4, 2025.
https://www.nature.com/articles/s41746-026-02354-6
9. AI-Assisted Detection Accuracy: Meta-Analysis
Rajih E, et al. "Improving Early Prostate Cancer Detection Through Artificial Intelligence: Evidence from a Systematic Review." Systematic review of 23 studies involving 23,270 patients published January 2015–April 2025. PRISMA 2020 guidelines; risk of bias assessed using QUADAS-AI tool. Findings: median AUC-ROC 0.88, sensitivity 0.86, specificity 0.83.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12609240/
10. AI in Digital Pathology and Gleason Grading
Authors not specified. "Artificial Intelligence-Assisted Prostate Cancer Diagnosis for Reduced Use of Immunohistochemistry." Retrospective analysis of prostate core needle biopsies across three pathology sites; AI model evaluated on difficult cases requiring IHC for diagnosis. AUC 0.951–0.993 for cancer detection on H&E-stained slides. ArXiv Preprint: 2504.00979, April 2026.
https://arxiv.org/pdf/2504.00979
11. Comprehensive Review: Current Applications of AI in Prostate Cancer
Rajih E, Bakhsh A, Borhan WM, Alqahtani SAM. "Utilization of Artificial Intelligence in Prostate Cancer Detection: A Comprehensive Review of Innovations in Screening and Diagnosis." Frontiers in Immunology, vol. 16, article 1670671, 2025. DOI: 10.3389/fimmu.2025.1670671. Published November 27, 2025.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12695749/
12. PARP Inhibitor Trial Landscape Analysis
Authors not specified. "PARP Inhibitors in the Treatment of Prostate Cancer: An Analysis of the Clinical Trial Landscape." Systematic analysis of 630 registered clinical trials as of April 25, 2025; 109 trials included. Findings: significant increase in trials 2012–2025; 39.4% multinational collaborative; primarily target PARP1 and PARP2.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12573472/
13. Exercise During ADT: Randomized Controlled Trial
Authors not specified. "Is Exercise During Androgen Deprivation Therapy Effective and Safe? A Randomized Controlled Trial." MedRxiv preprint. Published May 5, 2025. Evaluated efficacy and safety of current guideline-recommended exercise (3× weekly aerobic + 2× weekly resistance training) in men undergoing ADT.
https://www.medrxiv.org/content/10.1101/2025.05.05.25326963.full.pdf
14. Modern Integrative Prostate Cancer Diagnostics
Grobholz R, Burn F, Prause L. "Modern Integrative Prostate Cancer Diagnostics." Current Opinion in Urology, vol. 36, 2025. DOI: 10.1097/MOU.0000000000001361. Published December 10, 2025. Review of AI in radiological and pathological diagnosis; multimodal biomarkers for prognosis and treatment selection.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12893158/
15. Clinical Integration of AI: Ongoing Trial
Clinical Trial NCT05513638: "Safety and Accuracy of Artificial Intelligence-aided Precision MRI Assessment for the Optimization of Prostate Biopsy in Men With Suspicion of Prostate Cancer: A Multicenter Randomized Controlled Trial." Sponsor: The First Affiliated Hospital with Nanjing Medical University. Status: Recruiting. Randomizing to human-based vs. human-AI interactive interpretation of MRI for prostate cancer diagnosis.
https://clinicaltrials.gov/study/NCT05513638
Comments
Post a Comment